Literature DB >> 28258040

Angiomodulators in cancer therapy: New perspectives.

Lenka Varinska1, Peter Kubatka2, Jan Mojzis1, Anthony Zulli3, Katarina Gazdikova4, Pavol Zubor5, Dietrich Büsselberg6, Martin Caprnda7, Radka Opatrilova8, Iveta Gasparova9, Martin Klabusay10, Martin Pec11, Eitan Fibach12, Mariusz Adamek13, Peter Kruzliak14.   

Abstract

The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Anti-angiogenics; Cancer therapy; Galectins; Marine natural products; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28258040     DOI: 10.1016/j.biopha.2017.02.071

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 2.  Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

Authors:  Khalid El Bairi; Mariam Amrani; Said Afqir
Journal:  Cancer Med       Date:  2018-05-06       Impact factor: 4.452

3.  Rab5 regulates the proliferation, migration and invasion of glioma cells via cyclin E.

Authors:  Zhao Jian; Lianglong Zhang; Liang Jin; Weitu Lan; Wei Zhang; Guiyan Gao
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

Review 4.  Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis.

Authors:  Ashwaq Hamid Salem Yehya; Muhammad Asif; Sven Hans Petersen; Ayappa V Subramaniam; Koji Kono; Amin Malik Shah Abdul Majid; Chern Ein Oon
Journal:  Medicina (Kaunas)       Date:  2018-03-25       Impact factor: 2.430

5.  Kochia scoparia seed extract suppresses VEGF-induced angiogenesis via modulating VEGF receptor 2 and PI3K/AKT/mTOR pathways.

Authors:  Hyun-Dong Cho; Jeong-Ho Kim; Jun-Kyu Park; Seong-Min Hong; Du-Hyun Kim; Kwon-Il Seo
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

6.  Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells.

Authors:  Li Yanwei; Yang Yinli; Zhanyu Pan
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-13       Impact factor: 2.629

7.  β-Escin Effectively Modulates HUVECS Proliferation and Tube Formation.

Authors:  Lenka Varinská; Lenka Fáber; Martin Kello; Eva Petrovová; Ľudmila Balážová; Peter Solár; Matúš Čoma; Peter Urdzík; Ján Mojžiš; Emil Švajdlenka; Pavel Mučaji; Peter Gál
Journal:  Molecules       Date:  2018-01-17       Impact factor: 4.411

8.  Investigation of Different Molecular Weight Fucoidan Fractions Derived from New Zealand Undaria pinnatifida in Combination with GroA Therapy in Prostate Cancer Cell Lines.

Authors:  Xu Yang; Sheng Wang; Sari Schokoroy Trangle; Yan Li; William Lindsey White; Jinyao Li; Tianlei Ying; Qingjun Kong; Yu Zhao; Jun Lu
Journal:  Mar Drugs       Date:  2018-11-18       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.